Table 3.
The adjusted ORs for the association of SIRI with the prevalence of NAFLD in adults in the United States from NHANES 2017–2018.
| SIRI | Model 1 | Model 2 | Model 3 |
|---|---|---|---|
| OR (95 %CI) | OR (95 %CI) | OR (95 %CI) | |
| Q1 | Ref. | Ref. | Ref. |
| Q2 | 0.88 (0.60, 1.28) | 0.90 (0.60, 1.34) | 0.77 (0.48, 1.23) |
| Q3 | 1.04 (0.72, 1.52) | 0.91 (0.61, 1.36) | 0.79 (0.50, 1.24) |
| Q4 | 1.13 (0.77, 1.64) | 0.96 (0.64, 1.45) | 0.94 (0.60, 1.47) |
| P for trend | 0.379 | 0.895 | 0.214 |
Abbreviations: SIRI, system inflammation response index; NAFLD, non-alcoholic fatty liver disease; Q1, 0.120–0.632; Q2, 0.633–0.924; Q3, 0.925–1.371; Q4, 1.372–10.890; OR, odd ratio; CI, confidence interval. Model 1: age, sex and race/ethnicity. Model 2: model 1 variables plus education level, marital status, family poverty income ratio, the complication of hypertension, and diabetes mellitus, smoke status, drink status, and body mass index. Model 3 was adjusted for model 2 variables plus the complication of coronary heart disease, congestive heart failure, angina pectoris, heart attack, and stroke, mean energy intake, waist circumference, fast glucose, hemoglobin, high-sensitivity C-reactive protein, alanine aminotransferase, aspartate amino transferase, gamma-glutamyl transpeptidase, high-density lipoprotein-cholesterol, total cholesterol, triglyceride, blood urea nitrogen, uric acid, serum creatinine, and estimated glomerular filtration rate.